Skip to main content
. 2022 Jun 15;14(6):4192–4206.

Table 6.

Documents published on H101 from 2020 to 2021

Title Published year Name of published journals/conferences IF/Core Journals
A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma 2020 Cells SCI (IF=6.602)
A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: A retrospective cohort study 2021 Frontiers in Oncology SCI (IF=6.244)
A Review on the Advances and Challenges of Immunotherapy for Head and Neck Cancer 2021 Cancer Cell Int. SCI (IF=5.721)
Clinical Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined with Chemotherapy for Advanced Gastric Carcinoma 2021 Scientific Reports SCI (IF=4.371)
Clinical Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined with Chemotherapy for Advanced Cervical Cancer 2021 Scientific Reports SCI (IF=4.371)
Successful treatment of a 19-year-old patient with locally advanced clear cell adenocarcinoma of the uterine cervix using recombinant human adenovirus type 5 (Oncorine) combined with chemoradiotherapy: a case report 2021 Annals of Translational Medicine SCI (IF=3.932)
Recombinant Human Adenovirus Type 5 (Oncorine) Reverses Resistance to Immune Checkpoint Inhibitor in a Patient with Recurrent Non-Small Cell Lung Cancer: A Case Report 2021 Thoracic Cancer SCI (IF=3.504)
Advanced Hepatocellular Carcinoma Treated by Radiofrequency Ablation Combined with Oncolytic Virus and Anti-PD-1 Antibody Therapy: A Case Report and Literature Review 2021 Journal of International Medical Research SCI (IF=1.673)
The Efficacy and Safety of Recombinant Human Type-5 Adenovirus H101 in the Treatment of Intermediate to Advanced Solid Tumors: A Systematic Review and Meta-Analysis 2021 Translational Cancer Research SCI (IF=1.24)
Shanghai Expert Consensus on the Clinical Application of Oncolytic Viruses in the Treatment of Malignant Tumors (2021 Edition) 2021 China Oncology CSTPCD, PKU
Progress in Treatment of Breast Cancer with Oncolytic Viruses 2020 Chinese Journal of Clinical Oncology CSTPCD, PKU
Progress in Clinical Application of Oncolytic Virus Anti-Tumor Therapy 2021 Chinese Journal of Clinical Oncology CSTPCD, PKU
Progress in Application of Recombinant Human Adenovirus Type 5 Injection in Different Solid Tumors 2021 Chongqing Medical Journal CSTPCD, PKU
Recombinant Human Adenovirus Type 5 Injection Combined with Haploidentical Natural Killer Cell Immunotherapy for Ovarian Cancer Malignant Peritoneal Effusion: A Case Report 2020 China Journal of Modern Medicine CSTPCD, PKU
Aspergillus A (TSA) Enhances the Antitumor Activity of H101 Virus in Thymic Carcinoma by Up-Regulating Coxsackievirus and Adenoviral Receptor (CAR) Expression Through Inhibition of MAPK/ERK Pathway 2020 Chinese Journal of Microbiology and Immunology CSTPCD, PKU
Clinical Study of Local Intratumoral Injection of Recombinant Human Adenovirus Type 5 in the Treatment of Advanced Liver Cancer 2021 China Modern Doctor No Core Journal
ASCO Poster of Oncorine Science and Technology Commission Study Protocol-Summary of Colorectal Cancer Liver Metastasis Cases 2021 ASCO
Clinical Efficacy and Local Immune Response Evaluation of Intraperitoneal Injection of Oncolytic Virus in Malignant Ascites 2021 CSCO
CSCO Conference Live Broadcast of Oncorine Science and Technology Commission Study Protocol - Summary of Colorectal Cancer Liver Metastases 2020 CSCO
Study Protocol CSCO Poster of Oncorine Science and Technology Commission - Summary of Lung Cancer Metastasis Cases 2020 CSCO
CSCO Poster of Oncorine Science and Technology Commission Study Protocol - Summary of Melanotic Cancer Metastasis Cases 2020 CSCO

IF, Impact Factor; SCI, Science Citation Index; ASCO, American Society of Clinical Oncology; CSCO, Chinese Society of Clinical Oncology; CSTPCD, Chinese Scientific Papers and Citation Database; PKU, Chinese Core Journal Criterion of Peking University.